Results 21 to 30 of about 60,894 (286)

Co-evolution of Vaccination Behavior and Perceived Vaccination Risk can lead to a Stag-Hunt like Game [PDF]

, 2022
Voluntary vaccination is effective to prevent infectious diseases from spreading. Both vaccination behavior and cognition of the vaccination risk play important roles in individual vaccination decision making. However, it is not clear how the co-evolution of the two shapes the population-wide vaccination behavior.
arxiv   +1 more source

Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report

Journal of Medical Case Reports, 2017
Background The United States Advisory Committee on Immunization Practices recommends administration of the 13-valent pneumococcal conjugate vaccine in series with the 23-valent pneumococcal polysaccharide vaccine for prevention of pneumonia in the ...
Pierre Tawfik, Elie Gertner, Charlene E. McEvoy   +2 more
doaj   +1 more source

Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine [PDF]

Infectious Disease Clinics of North America, 2015
Universal immunization of infants and toddlers with pneumococcal conjugate vaccines over the last 15 years has dramatically altered the landscape of pneumococcal disease. Decreases in invasive pneumococcal disease, all-cause pneumonia, empyema, mastoiditis, acute otitis media, and complicated otitis media have been reported from multiple countries in ...
Inci Yildirim, Kimberly M. Shea, Stephen I. Pelton, Stephen I. Pelton   +3 more
openaire   +3 more sources

Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis [PDF]

New England Journal of Medicine, 2009
Invasive pneumococcal disease declined among children and adults after the introduction of the pediatric heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its effect on pneumococcal meningitis is unclear.We examined trends in pneumococcal meningitis from 1998 through 2005 using active, population-based surveillance data from eight sites in
Matthew R. Moore, Nancy M. Bennett, Arthur Reingold, Monica M. Farley, William Schaffner, Heather E. Hsu, Lee H. Harrison, Lee H. Harrison, Susan Petit, Kathleen A. Shutt, James H. Jorgensen, Bernard Beall, Catherine Lexau, Allen S. Craig, Cynthia G. Whitney, Ann Thomas   +15 more
openaire   +3 more sources

Accurate Measures of Vaccination and Concerns of Vaccine Holdouts from Web Search Logs [PDF]

, 2023
To design effective vaccine policies, policymakers need detailed data about who has been vaccinated, who is holding out, and why. However, existing data in the US are insufficient: reported vaccination rates are often delayed or missing, and surveys of vaccine hesitancy are limited by high-level questions and self-report biases. Here, we show how large-
arxiv   +1 more source

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

The Pediatric Infectious Disease Journal, 2020
Supplemental Digital Content is available in the text. Background: Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots ...
H. Platt, D. Greenberg, B. Tapiéro, R. Clifford, N. Klein, D. Hurley, T. Shekar, Jianing Li, Kim Hurtado, Shu-Chih Su, Katrina M. Nolan, C. Acosta, Richard D. McFetridge, K. Bickham, L. Musey   +14 more
semanticscholar   +1 more source

Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review.

PLoS ONE, 2019
BackgroundDespite the widespread implementation of the pneumococcal conjugate vaccine, Streptococcus pneumoniae remains the leading cause of severe pneumonia associated with mortality among children less than 5 years of age worldwide, with the highest ...
James Samwel Ngocho, Best Magoma, Gaudencia Alois Olomi, Michael Johnson Mahande, Sia Emmanueli Msuya, Marien Isaäk de Jonge, Blandina Theophil Mmbaga   +6 more
doaj   +1 more source

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Emerging Infectious Diseases, 2015
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1,
Mirjam J. Knol, Gertjan H.J. Wagenvoort, Elisabeth A.M. Sanders, Karin Elberse, Bart J. Vlaminckx, Hester E. de Melker, Arie van der Ende   +6 more
doaj   +1 more source

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR. Morbidity and mortality weekly report, 2019
Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co.
Almea M Matanock, Grace M. Lee, R. Gierke, Miwako Kobayashi, A. Leidner, T. Pilishvili   +5 more
semanticscholar   +1 more source

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey

Human Vaccines & Immunotherapeutics, 2017
Invasive pneumococcal infections among children are a serious public health problem in many countries, including Turkey. Pneumococcal conjugate vaccine has been included in Turkey's National Immunization Programme since 2009.
Ayşe Büyükcam, Hüseyin Güdücüoğlu, Kamuran Karaman, Venhar Gürbüz, Emil Aliyev, Ateş Kara, Mehmet Ceyhan   +6 more
doaj   +1 more source